Does the media prefer ARCT or PMN?

In the previous week, Arcturus Therapeutics had 7 more articles in the media than Promis Neurosciences. MarketBeat recorded 9 mentions for Arcturus Therapeutics and 2 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.37 beat Arcturus Therapeutics' score of 0.16 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Promis Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, PMN or AGMB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Promis Neurosciences N/A N/A -$39.72M -$8.54 N/A AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Is PMN or AGMB more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Promis Neurosciences N/A -143.09% -109.15% AgomAb Therapeutics N/A N/A N/A

Does the media prefer PMN or AGMB?

In the previous week, Promis Neurosciences and Promis Neurosciences both had 2 articles in the media. Promis Neurosciences' average media sentiment score of 0.37 beat AgomAb Therapeutics' score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Promis Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, CABA or PMN?

Promis Neurosciences is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A Promis Neurosciences N/A N/A -$39.72M -$8.54 N/A

Is CABA or PMN more profitable?

Cabaletta Bio's return on equity of -128.27% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -128.27% -95.47% Promis Neurosciences N/A -143.09% -109.15%

Does the media favor PRTA or PMN?

In the previous week, Prothena had 4 more articles in the media than Promis Neurosciences. MarketBeat recorded 6 mentions for Prothena and 2 mentions for Promis Neurosciences. Prothena's average media sentiment score of 1.18 beat Promis Neurosciences' score of 0.37 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Promis Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, ARTV or PMN?

Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artiva Biotherapeutics N/A N/A -$83.86M -$3.30 N/A Promis Neurosciences N/A N/A -$39.72M -$8.54 N/A

Is ARTV or PMN more profitable?

Artiva Biotherapeutics' return on equity of -53.86% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -53.86% -48.16% Promis Neurosciences N/A -143.09% -109.15%

Does the media favor ARTV or PMN?

In the previous week, Artiva Biotherapeutics had 3 more articles in the media than Promis Neurosciences. MarketBeat recorded 5 mentions for Artiva Biotherapeutics and 2 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.37 beat Artiva Biotherapeutics' score of 0.28 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Promis Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Promis Neurosciences (PMN) Competitors

$12.94 -0.64 (-4.71%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$12.96 +0.02 (+0.15%)

As of 04:01 AM Eastern

Compare

PMN vs. ARCT, AGMB, CABA, PRTA, and ARTV

Should you buy Promis Neurosciences stock or one of its competitors? Promis Neurosciences's main competitors and comparable companies include Arcturus Therapeutics (ARCT), AgomAb Therapeutics (AGMB), Cabaletta Bio (CABA), Prothena (PRTA), and Artiva Biotherapeutics (ARTV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Promis Neurosciences compare to Arcturus Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Promis Neurosciences has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%
Promis Neurosciences	N/A	-143.09%	-109.15%

In the previous week, Arcturus Therapeutics had 7 more articles in the media than Promis Neurosciences. MarketBeat recorded 9 mentions for Arcturus Therapeutics and 2 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.37 beat Arcturus Therapeutics' score of 0.16 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Promis Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Promis Neurosciences has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	4.61	-$65.78M	-$3.31	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A

Arcturus Therapeutics presently has a consensus price target of $23.00, suggesting a potential upside of 72.93%. Promis Neurosciences has a consensus price target of $34.00, suggesting a potential upside of 162.75%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Promis Neurosciences is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Arcturus Therapeutics has a beta of 2.48, indicating that its stock price is 148% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

Summary

Arcturus Therapeutics beats Promis Neurosciences on 9 of the 16 factors compared between the two stocks.

How does Promis Neurosciences compare to AgomAb Therapeutics?

Promis Neurosciences (NASDAQ:PMN) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

50.1% of Promis Neurosciences shares are held by institutional investors. 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

AgomAb Therapeutics' return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-143.09%	-109.15%
AgomAb Therapeutics	N/A	N/A	N/A

In the previous week, Promis Neurosciences and Promis Neurosciences both had 2 articles in the media. Promis Neurosciences' average media sentiment score of 0.37 beat AgomAb Therapeutics' score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Promis Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Promis Neurosciences presently has a consensus price target of $34.00, indicating a potential upside of 162.75%. AgomAb Therapeutics has a consensus price target of $37.50, indicating a potential upside of 248.19%. Given AgomAb Therapeutics' higher probable upside, analysts clearly believe AgomAb Therapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

Promis Neurosciences beats AgomAb Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Promis Neurosciences compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Cabaletta Bio has a beta of 3.27, suggesting that its share price is 227% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market.

50.1% of Promis Neurosciences shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cabaletta Bio's return on equity of -128.27% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Promis Neurosciences	N/A	-143.09%	-109.15%

Cabaletta Bio currently has a consensus price target of $15.33, suggesting a potential upside of 590.69%. Promis Neurosciences has a consensus price target of $34.00, suggesting a potential upside of 162.75%. Given Cabaletta Bio's higher possible upside, analysts clearly believe Cabaletta Bio is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

In the previous week, Promis Neurosciences had 2 more articles in the media than Cabaletta Bio. MarketBeat recorded 2 mentions for Promis Neurosciences and 0 mentions for Cabaletta Bio. Promis Neurosciences' average media sentiment score of 0.37 beat Cabaletta Bio's score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Cabaletta Bio	Neutral
Promis Neurosciences	Neutral

Promis Neurosciences is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A

Summary

Cabaletta Bio beats Promis Neurosciences on 8 of the 14 factors compared between the two stocks.

How does Promis Neurosciences compare to Prothena?

Prothena (NASDAQ:PRTA) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Promis Neurosciences has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Promis Neurosciences	N/A	-143.09%	-109.15%

97.1% of Prothena shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 10.4% of Prothena shares are held by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Prothena had 4 more articles in the media than Promis Neurosciences. MarketBeat recorded 6 mentions for Prothena and 2 mentions for Promis Neurosciences. Prothena's average media sentiment score of 1.18 beat Promis Neurosciences' score of 0.37 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Promis Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Promis Neurosciences has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	46.94	-$244.09M	-$0.84	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A

Prothena currently has a consensus target price of $24.57, suggesting a potential upside of 183.08%. Promis Neurosciences has a consensus target price of $34.00, suggesting a potential upside of 162.75%. Given Prothena's higher possible upside, equities research analysts clearly believe Prothena is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Prothena has a beta of -0.33, suggesting that its stock price is 133% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market.

Summary

Prothena beats Promis Neurosciences on 10 of the 16 factors compared between the two stocks.

How does Promis Neurosciences compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Artiva Biotherapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market.

Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	N/A	N/A	-$83.86M	-$3.30	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A

Artiva Biotherapeutics' return on equity of -53.86% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
Promis Neurosciences	N/A	-143.09%	-109.15%

In the previous week, Artiva Biotherapeutics had 3 more articles in the media than Promis Neurosciences. MarketBeat recorded 5 mentions for Artiva Biotherapeutics and 2 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.37 beat Artiva Biotherapeutics' score of 0.28 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Promis Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

50.1% of Promis Neurosciences shares are held by institutional investors. 1.8% of Artiva Biotherapeutics shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Artiva Biotherapeutics presently has a consensus price target of $39.00, suggesting a potential upside of 405.18%. Promis Neurosciences has a consensus price target of $34.00, suggesting a potential upside of 162.75%. Given Artiva Biotherapeutics' higher possible upside, research analysts plainly believe Artiva Biotherapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Artiva Biotherapeutics beats Promis Neurosciences on 7 of the 13 factors compared between the two stocks.

Get Promis Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMN vs. The Competition

Export

Metric	Promis Neurosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$121.78M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-1.52	13.88	274.08	25.69
Price / Sales	N/A	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	-22.31	15.40	10.47	6.32
Net Income	-$39.72M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-3.86%	-1.70%	-0.67%	0.17%
1 Month Performance	-12.57%	-6.17%	-3.17%	-3.27%
1 Year Performance	24.84%	30.67%	15.14%	5.58%

Promis Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMN Promis Neurosciences	3.5624 of 5 stars	$12.94 -4.7%	$34.00 +162.8%	+26.1%	$121.78M	N/A	N/A	11	News Coverage
ARCT Arcturus Therapeutics	3.0858 of 5 stars	$15.60 -1.5%	$23.00 +47.4%	-34.4%	$450.22M	$82.03M	N/A	111	News Coverage
AGMB AgomAb Therapeutics	3.4661 of 5 stars	$11.41 -6.2%	$37.50 +228.7%	N/A	$440.64M	N/A	N/A	62
CABA Cabaletta Bio	2.2194 of 5 stars	$2.49 -4.2%	$15.33 +515.8%	-8.3%	$439.97M	N/A	N/A	158
PRTA Prothena	3.3941 of 5 stars	$8.24 -1.1%	$24.57 +198.2%	+4.5%	$436.10M	$9.68M	N/A	67	Positive News Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMN) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Promis Neurosciences (PMN) Competitors

PMN vs. ARCT, AGMB, CABA, PRTA, and ARTV

How does Promis Neurosciences compare to Arcturus Therapeutics?

Summary

How does Promis Neurosciences compare to AgomAb Therapeutics?

Summary

How does Promis Neurosciences compare to Cabaletta Bio?

Summary

How does Promis Neurosciences compare to Prothena?

Summary

How does Promis Neurosciences compare to Artiva Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN vs. The Competition

Promis Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Promis Neurosciences (PMN) Competitors

PMN vs. ARCT, AGMB, CABA, PRTA, and ARTV

How does Promis Neurosciences compare to Arcturus Therapeutics?

Is ARCT or PMN more profitable?

Does the media prefer ARCT or PMN?

Do insiders and institutionals have more ownership in ARCT or PMN?

Which has higher earnings & valuation, ARCT or PMN?

Do analysts rate ARCT or PMN?

Which has more volatility and risk, ARCT or PMN?

Summary

How does Promis Neurosciences compare to AgomAb Therapeutics?

Which has better earnings & valuation, PMN or AGMB?

Do institutionals & insiders believe in PMN or AGMB?

Is PMN or AGMB more profitable?

Does the media prefer PMN or AGMB?

Do analysts rate PMN or AGMB?

Summary

How does Promis Neurosciences compare to Cabaletta Bio?

Which has more risk and volatility, CABA or PMN?

Do institutionals and insiders have more ownership in CABA or PMN?

Is CABA or PMN more profitable?

Do analysts rate CABA or PMN?

Does the media prefer CABA or PMN?

Which has stronger earnings and valuation, CABA or PMN?

Summary

How does Promis Neurosciences compare to Prothena?

Is PRTA or PMN more profitable?

Do insiders & institutionals have more ownership in PRTA or PMN?

Does the media favor PRTA or PMN?

Which has higher earnings & valuation, PRTA or PMN?

Do analysts rate PRTA or PMN?

Which has more risk & volatility, PRTA or PMN?

Summary

How does Promis Neurosciences compare to Artiva Biotherapeutics?

Which has more risk and volatility, ARTV or PMN?

Which has stronger valuation & earnings, ARTV or PMN?

Is ARTV or PMN more profitable?

Does the media favor ARTV or PMN?

Do institutionals and insiders have more ownership in ARTV or PMN?

Do analysts recommend ARTV or PMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN vs. The Competition

Promis Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools